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ABSTRACT 
UBE4B LEVELS DETERMINE THE EFFICACY OF EGFR AND STAT5 
INHIBITORS IN TREATMENT RESISTANT NEUROBLASTOMA 
David J. Savage, B.A. 
Advisory Professor: Andrew Bean, Ph.D. 
 
 
Neuroblastoma is the most common malignancy in infants. Overexpression of the 
epidermal growth factor receptor (EGFR) in neuroblastoma tumors can result in enhanced 
EGFR signaling, uncontrolled proliferation, and may provide a mechanism for chemotherapy 
resistance. UBE4B, an E3/E4 ubiquitin ligase, ubiquitinates the EGFR and promotes its 
lysosomal degradation ultimately attenuating EGFR signaling. Interestingly, the UBE4B gene 
lies in a chromosomal region (1p36) whose loss is correlated with poor patient outcomes due 
to inefficient EGFR degradation and enhanced cell proliferation. We examined whether 
depletion of UBE4B in a chemoresistant neuroblastoma cell line would affect tumor responses 
to drugs that specifically target selected proteins that are upregulated in the absence of UBE4B. 
UBE4B depletion in a resistant neuroblastoma cell line resulted in a number of proteins whose 
levels were altered, including an increase in EGFR and STAT5a levels. We observed that 
treatment with Cetuximab, a therapeutic antibody targeting the EGFR, significantly inhibited 
the proliferation of neuroblastoma cells depleted of UBE4B. Addition of a STAT5 inhibitor 
potentiated the Cetuximab-induced inhibition of proliferation, reduced migration, and 
enhanced apoptosis in UBE4B-depleted neuroblastoma cells more than either drug treatment 
alone. Thus, screening resected patient tumors for 1p36 status and UBE4B levels may enable 
a novel treatment strategy in which selected patients who have low UBE4B-expressing tumors 
may benefit from simultaneously targeting multiple EGFR signaling pathways.  
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CHAPTER 1 - Introduction 
 
1.1 Characteristics, Incidence, and Prevalence of Neuroblastoma 
 
Neuroblastoma is a malignant (1), embryonal tumor that arises from neural crest-
derived cells of the sympathetic nervous system (2). It is the most frequently diagnosed tumor 
in the first year of life, and the most common extracranial solid tumor in children (3). The 
disease can spread from the head to the pelvis, but in a majority of cases the tumor arises from 
the adrenal medulla (Figure 1) (4, 5). Neuroblastoma represents about 8% of all childhood 
cancers (3), and more than 600 new cases of neuroblastoma are diagnosed in the United States 
annually (6). More than 70% of patients are diagnosed with neuroblastoma after metastasis has 
occurred (7). 
.  
Figure 1. Full-body CT scan demonstrating common locations for 
neuroblastoma 
This figure demonstrates a computed tomography (CT) scan of a child showing an 
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adrenal mass near the spine where it crosses the midline axis of the body.  
Hallett, Andrew and Heidi Traunecker. 2012. “A Review and Update on 
Neuroblastoma.” Paediatrics and Child Health 22(3):103–7. Retrieved 
(http://dx.doi.org/10.1016/j.paed.2011.08.005). 
Used with permission from from Elsevier. 
 
The symptoms of neuroblastoma can be quite variable and are dependent upon the 
tumor site (8). Tumor compression on the spinal cord can lead to lower extremity paralysis, 
thoracic tumors can cause a Horner’s syndrome (anhidrosis, miosis, and partial ptosis) of the 
eye, liver tumors can cause abdominal swelling, metastasis to the bone marrow can cause 
hematologic disorders, and adrenal medullary tumors can cause abnormal catecholamine 
production (5). This pleiotropic set of symptoms and the rarity of the disease (3) can make it 
challenging to detect.  
The long-term prognosis for neuroblastoma worsens with increased age of the patient 
at diagnosis (9). Patients who are diagnosed at ages older than 18 months, who either have a 
metastasis or who have tumors with unfavorable histology, or NMYC oncogene amplification, 
tend to have a worse prognosis (4, 10).  In cases of neuroblastoma relapse, treatment options 
are limited since these tumor cells can rapidly develop resistance to conventional 
chemotherapeutics (11). 
 
1.2 Stratification of Neuroblastoma’s Severity 
 
Stratification of the severity of neuroblastoma requires assessing a number of factors. 
These include the stage of disease (12), age of the patient, whether or not the NMYC oncogene 
is amplified, histopathology of the tumor, and chromosome abnormalities (9, 13). One such 
common abnormality is a loss of heterozygosity (LOH) in the 1p chromosomal region (Figure 
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2), which is associated with a decreased response to treatment, a lower event-free, and a lower 
overall survival (14–16). Approximately one-third of neuroblastoma cases display deletions 
within the 1p36 chromosomal region (14–17). One gene within this region whose deletion has 
been shown to correlate with poor prognosis is the ubiquitin ligase UBE4B, which regulates 
growth receptor protein trafficking in the endocytic pathway (18, 19). 
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Figure 2. UBE4B on the 1p chromosome site  
Deletions at the 1p36 chromosome site occur in one third of neuroblastomas. This is 
the site of the ubiquitin ligase, UBE4B, a regulator of growth factor degradation in the 
endocytic pathway. 
Carén, H., A. Holmstrand, R. M. Sjöberg, and T. Martinsson. 2006. “The Two Human 
Homologues of Yeast UFD2 Ubiquitination Factor, UBE4A and UBE4B, Are 
Located in Common Neuroblastoma Deletion Regions and Are Subject to 
Mutations in Tumours.” European Journal of Cancer 42(3):381–87. 
Used with permission from from Elsevier. 
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1.3 Conventional Treatment of Neuroblastoma and Long-term Prognosis 
 
The treatment for neuroblastoma depends on the risk stratification of the patient. 
Patients are divided into low, intermediate, and high-risk groups (13). Therapy is multi-modal 
and may include observation, surgery, chemotherapy, radiotherapy, stem cell transplantation, 
differentiation therapy, and/or immunotherapy (8). While patients with non-metastatic, 
minimally invasive neuroblastoma may be disease-free following surgery alone, chemotherapy 
is used for patients with invasive or metastatic disease (20). Frontline chemotherapeutics for 
neuroblastoma are non-specific and affect non-cancerous cells as well (21). They function 
through either inducing DNA damage or interfering with the mitotic spindle to interrupt cell 
division (22). This induces cell death and acts in a greater degree on rapidly proliferating 
neuroblastoma cells, but it can affect normal cells, too (23). This explains many of the common 
late side effects of chemotherapy treatment such as hearing loss, pulmonary fibrosis, and 
cardiotoxicity (24).  
Frontline chemotherapy, also called induction chemotherapy, for high risk 
neuroblastoma includes a combination of cisplatin, vincristine, carboplatin, etoposide, and 
cyclophosphamide (25). Each of these agents works by a different mechanism of action to kill 
cancer cells, but broadly they target either DNA replication or cell division to cause irreversible 
damage leading to apoptosis (23).  Cisplatin, carboplatin (a cisplatin analog), and 
cyclophosphamide act by alkylating DNA bases. Subsequently, DNA repair enzymes cause 
DNA damage while attempting to repair the alkylation, which ultimately leads to cell death 
(22). Vincristine binds to the protein tubulin to interfere with cell division in mitosis (26). 
Etoposide is a topoisomerase II inhibitor that prevents DNA unwinding during replication, 
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leading to apoptotic cell death (27). A combination of drug agents in the frontline treatment 
phase delays the onset of selective chemotherapy resistance (28). Thus, using a combination 
of chemotherapy agents that act by different mechanisms to interfere with cell growth in the 
initial phase of treatment can increase the likelihood of a neuroblastoma patient becoming 
cancer free. 
Beyond traditional cytotoxic chemotherapy, other treatments are used for high risk 
patients.  They may be treated with myeloablation followed by autologous stem cell transplant 
for neuroblastoma that may have spread to the bone marrow (29). Subsequent possible 
treatments include forced cell differentiation with 13-cis-retinoic acid or targeted anti-GD2 
antibody therapy which triggers cytotoxicity through an immune response (25). Retinoic acid 
is used to treat residual disease after myeloablative therapy, and acts to force growth arrest and 
terminal maturation of neural tissue (30). The anti-GD2 antibody works by binding to 
neuroblastoma cells, which overexpress the ganglioside GD2. This induces cell death through 
complement-mediated cytotoxicity and activation of the immune response. (31). High risk 
neuroblastoma patients often require more complex treatment approaches to effectively treat 
their disease. 
The long-term prognosis for neuroblastoma depends on a patient’s risk classification 
and tumor stage at the time of initial diagnosis (26).  Patients  in the low risk category can 
expect a 92% event-free survival and 96% probability of overall survival (32, 33). Patients at 
intermediate risk disease have an overall survival rate of 80% (34, 35), while patients with high 
risk disease have an event-free survival of less than 50% despite multimodal therapy (36, 37). 
Thus, while clinical outcomes are good for low and intermediate risk patients, new treatment 
strategies are needed for high risk patients to improve their outcomes. 
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1.4 Mechanisms of Neuroblastoma Chemotherapy Resistance 
 
High risk patients with a tumor relapse have poor outcomes in part because of the 
development of chemotherapy resistance (4, 38). Some common cellular resistance 
mechanisms include decreased chemotherapy drug uptake (39), increased drug efflux (40), 
increased DNA damage repair (41), failure of cell death pathways (42), and increased growth 
factor receptor expression at the cell surface (Figure 3) (18). Amplification of the MYCN gene, 
a poor prognostic indicator in neuroblastoma, upregulates ABC transporters in cell membranes 
that promote efflux of chemotherapy drugs from cells (40, 43). Chemotherapy resistance may 
also be promoted by growth factor receptors, like the epidermal growth factor receptor 
(EGFR), which is increased in amounts in other neural cancers leading to conventional 
chemotherapy resistance by enhancing proliferation (44). EGFR protein levels are high in 
many in vitro neuroblastoma cell lines and patient tumor biopsies (1). There are many 
mechanisms of resistance in neuroblastoma that affect drug uptake and cellular response to 
chemotherapy, and increased growth factor-stimulated signaling may be another mechanism 
of resistance. 
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Figure 3. Common chemotherapy resistance mechanisms in cancer 
Diagram of common mechanisms of chemotherapy resistance in cancer. Aside from 
increased growth factor signaling, these mechanisms lower the intracellular amount 
of drug or change the intended protein targets such that effects on cell division, 
DNA replication, or signaling pathways are not lethal. Modified from: 
El-Awady, Raafat et al. 2017. “The Role of Eukaryotic and Prokaryotic ABC 
Transporter Family in Failure of Chemotherapy.” Frontiers in Pharmacology 
7(JAN):1–15. 
 
1.5 EGFR and the Endocytic Pathway 
 
The endocytic pathway internalizes membrane proteins and transports them for 
recycling, transit to other intracellular compartments, or degradation (45). It is an important 
regulator of EGFR-mediated signaling for the proliferation of neuroblastoma (46). EGFR may 
be internalized at the plasma membrane, trafficked through the endocytic pathway, and sorted, 
into a pathway that will result in its lysosomal degradation or will cause the receptor to be 
recycled for reuse (47). There are five ligands known to bind EGFR: epidermal growth factor 
(EGF),  transforming growth factor alpha (TGF-α), amphiregulin, epiregulin, and betacellulin 
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(48). These ligands may have different fates during the trafficking process, but EGF binding 
enhances degradation of the receptor as a means of attenuating signaling (49).  
Upon ligand binding, the EGFR dimerizes, which then triggers autophosphorylation of 
the tyrosine residues in the cytoplasmic tail of the receptor to initiate endocytosis. Binding of 
EGF or TGF-α specifically results in clathrin-mediated endocytosis (47).  In this process, 
clathrin adapter protein 2 (AP2) protein complexes are recruited to the plasma membrane, 
which then recruit clathrin (50). As membrane invagination continues and clathrin 
polymerizes, AP2 stabilizes the coated pit. Next, the GTPase dynamin is required to induce 
fission of a deep clathrin-coated pit and its cargo from the plasma membrane, resulting in the 
formation of an endocytic vesicle (45). By the end of this initial step in the endocytic pathway, 
an early endosome is formed which can then be sorted to its destination. 
Internalized EGFRs follow an endocytic itinerary in which they pass through early 
endosomes and late endosomes/multivesicular bodies (MVB) prior to the lysosome for 
degradation. Ubiquitination of the cytoplasmic tail of EGFR allows recognition by the ESCRT 
machinery, a group of cytosolic protein complexes required for internalization from the 
endosomal membrane into intraluminal vesicles (ILVs), and subsequent degradation upon 
MVB-lysosome fusion (Figure 4) (51–58). Mono-ubiquitination of cargo at the plasma 
membrane can promote intracellular protein movement through the endocytic pathway, but it 
does not necessarily serve as a signal for lysosomal degradation (59).  Conversely, 
polyubiquitination of cargo at the membrane of early endosomes is a necessary step for 
receptor internalization into ILVs and subsequent degradation by the lysosome. (50, 60). 
Regulation of EGFR ubiquitination and degradation can affect the total amount of EGFR that 
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resides on the cell surface (46). The endocytic pathway can modulate EGFR-mediated 
signaling by affecting the number of receptors on the surface of cells.  
 
1.6 Ubiquitination and EGFR Degradation 
 
Ubiquitination is a key regulator of EGFR degradation (53, 61). EGFR may be 
ubiquitinated on lysine residues by the E3 ubiquitin ligase Cbl at the plasma membrane (61) 
or by the E3/E4 ubiquitin ligase UBE4B at the endosomal membrane (53). Ubiquitination is a 
necessary step for lysosomal sorting in the endocytic pathway (46). A dominant negative of 
Cbl (62) or a depletion of UBE4B (53) can lead to a decrease of EGFR lysosomal degradation. 
Lysine residues 29, 48, and 63 are targets of mono-ubiquitination by the E3 ligase Cbl (61), 
whereas UBE4B can attach ubiquitin at those lysine residues as well as lysine residues 6, 11, 
27, and 33 (63).  Another key difference between Cbl and UBE4B is that UBE4B can act as 
an E4 ligase (63). E4 ligases are capable of ubiquitin chain assembly to mediate 
polyubiquitination (64). Furthermore, ubiquitination by UBE4B can be counteracted by the de-
ubiquitinating enzyme USP8 (53). Ubiquitination is an essential step for endosomal sorting 
and lysosomal degradation of cargo in the endocytic pathway.  
The amount of UBE4B in neuroblastoma cells correlates with patient survival. The 
gene for UBE4B resides at the 1p36 chromosome site, which is commonly deleted in one-third 
of neuroblastomas (Figure 2) (14, 19, 65). Patients with lower levels of UBE4B have a poor 
prognosis compared to patients with normal levels (18), even when stratified by disease stage 
(19). Furthermore, it has been suggested that decreased UBE4B levels are a predictor of relapse 
in low and intermediate risk pediatric patients (19). Thus, the levels of UBE4B correlate with 
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neuroblastoma patient outcomes, and understanding how decreased UBE4B levels contribute 
to poor prognosis through the proteins that it regulates may aid in finding new treatment 
approaches. 
One way in which UBE4B may enhance the growth of neuroblastoma is through its 
regulation of EGFR. UBE4B protein levels in neuroblastoma patient biopsies are inversely 
proportional to EGFR protein levels (18). As the amount of cellular UBE4B decreases, the 
expression of EGFR increases and neuroblastoma cells may become more proliferative and 
resistant to conventional chemotherapy due to increased stimulation by pro-growth ligands in 
the environment (1).  Conversely, cancer cells expressing high protein levels of UBE4B are 
less responsive to EGF-stimulated growth and EGFR-targeted anti-proliferative therapy (18). 
Transiently depleted UBE4B can produce a two-fold increase in whole cell EGFR in cancer 
cells in vitro (53). Therefore, low levels of UBE4B may enhance proliferation and worsen 
patient outcomes. 
The UBE4B enzyme interacts with cargo proteins, like the epidermal growth factor 
receptor (EGFR), at the membrane of early endosomes to ubiquitinate them (53). The number 
of ubiquitin residues that are added determines whether modified cargo is degraded by the 
lysosome or recycled back to the cell’s surface (52). A decrease in the amount of cellular 
UBE4B can lead to decreased EGFR degradation due to decreased ubiquitination. Inactivation 
of the catalytic activity of UBE4B, which can lead to a dominant negative phenotype, has a 
similar effect of lessening EGFR degradation over time (53). Neuroblastoma cells 
overexpressing a catalytically inactive form of UBE4B, UBE4BP1140A, decrease their degradation 
of EGFR, while neuroblastoma cells overexpressing UBE4B increase the amount of EGFR 
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that they degrade (53). Thus, it appears that when UBE4B is depleted or inactivated, an 
increased amount of EGFR can result. 
Increased EGFR levels as a result of decreased amounts of UBE4B can lead to 
increased stimulation by growth factors (18) and increased pro-proliferative downstream 
signaling (53). The fact that stimulation by growth factors in vitro can enhance downstream 
signaling and cell growth provides some evidence that a portion of increased EGFR resides on 
the cellular surface. In cervical adenocarcinoma (HeLa) cells, transient depletion of UBE4B 
levels followed by stimulation with EGF leads to a significant rise in signaling in the pro-
proliferative MAPK/ERK signaling pathway (53). Moreover, neuroblastoma cells that 
overexpress UBE4B have reduced proliferation in response serum and EGF (18). These data 
suggest that the mechanism by which low UBE4B levels result in worse patient outcomes may 
involve increased growth factor-stimulated proliferation due to increased EGFR levels. 
 
Figure 4. Graphical depiction of EGFR traveling through the endocytic 
pathway  
 
UBE4B interacting with EGFR (blue) at the endosomal membrane during trafficking 
in the endocytic pathway. The degree of ubiquitination determines cargo fate of either 
lysosomal degradation (Lyso) or plasma membrane recycling. Polyubiquitination of 
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the cytosolic-facing segment of the EGFR causes it to be internalized into 
intraluminal vesicles of the MVB/late endosome. Degradation of the receptor then 
occurs after fusion with the lysosome. 
 
1.7 Mechanism of Cetuximab as a Treatment for Neuroblastoma 
 
Cetuximab (mAb C225 or Erbitux) is a monoclonal antibody that specifically binds to 
the EGF receptor (66). It interacts with the extracellular domain of the receptor blocking the 
ligand binding site (67). Binding of Cetuximab to EGFR also stimulates receptor 
internalization (68). Like other cargo that travels through the endocytic pathway, the receptor 
is ultimately either degraded in the lysosome or recycled (47). Cetuximab binding also induces 
antibody-dependent cell-mediated cytotoxicity (69). 
The benefit of Cetuximab is derived from blocking EGF binding to the EGFR and the 
drug’s effective reduction in growth factor receptors in a rapidly proliferating cancers (66, 70). 
The number of growth factor receptors has been shown to correlate with an increased rate of 
proliferation and resistance to chemotherapy agents that target cell division (71). Cetuximab 
has significant therapeutic benefit in treating colorectal cancer (72, 73) and cancers of the head 
and neck (74). In non-small cell lung cancer (NSCLC), Cetuximab is effective in patients with 
elevated levels of EGFR, regardless of whether those receptors have mutations (75). To date, 
however, Cetuximab has not been an effective treatment in neuroblastoma patients. In a phase 
1 clinical trial involving treatment of Cetuximab and irinotecan in pediatric solid tumors 
(which included just two neuroblastomas), there was no sustained or complete response in the 
neuroblastoma patients to the combination therapy (76). The patients in that trial were not 
differentiated by the amount of EGFR in their tumors and the sample size was small. In the 
case of non-small lung cancer, the greatest response to Cetuximab was observed when patients 
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were strategically selected based on elevated levels of EGFR (77).  Given the fact that one-
third of neuroblastomas have deletions of the chromosomal location containing the UBE4B 
locus (14, 19), it may be possible to strategically select neuroblastoma patients with low levels 
of UBE4B for Cetuximab treatment. 
 
1.8 Targeting Signaling Downstream of the EGF Receptor 
 
EGFR transmits signals through activation of many cytosolic signaling cascades, 
including Ras/Raf (78), phosphatidylinositol 3-kinase/Akt (79), Jak/STAT (80), phospholipase 
C (81), and Nck/PAK signaling pathways (82). Each of these pathways have been implicated 
in cell proliferation, and their constitutive activation, independent of EGFR ligand binding, can 
blunt the effect of inhibitors that target that receptor (83). Consequently, combination therapies 
that target a pathway downstream of EGFR can increase the efficacy of EGFR-targeted therapy 
(84). This combination therapy approach has been used successfully in non-small cell lung 
cancer using a Jak-2 inhibitor in combination with Cetuximab. In pre-clinical trials, this 
combination overcame resistance, synergistically, when compared to Cetuximab treatment 
alone (85). Similarly, an increased anti-proliferative effect has been observed in head and neck 
squamous cell carcinomas treated with a combination of a Jak-2/STAT3 inhibitor and 
Cetuximab (86). It may be possible to simultaneously target EGFR and one member of a 
downstream signaling pathway in order to produce an anti-proliferative effect in 
neuroblastoma tumor cells. 
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1.9 Design of this Study 
 
One of the goals of our research was to understand the role of UBE4B in regulating the 
levels of other proteins and mediating the chemotherapy response in neuroblastoma. I created 
a model neuroblastoma chemotherapy-resistant cell line where UBE4B was depleted to 
undetectable levels. This model was used to test several specific hypotheses: 
 
1. Does stable depletion of UBE4B lead to increased EGFR in neuroblastoma? 
2. Does this increase in EGFR make cells more sensitive to EGFR-targeted drug 
agents? 
3. Does a depletion of UBE4B lead to other protein changes in neuroblastoma? 
4. Can proteins that increase in amount due to UBE4B depletion be targeted to 
reduce neuroblastoma cell growth in vitro?  
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Figure 5. Graphical depiction of UBE4B’s ubiquitination role in EGFR 
degradation  
UBE4B ubiquitination determines the fate of endosomal cargo like EGFR that is 
trafficked through the endocytic pathway. Understanding which proteins are elevated 
as a result of a UBE4B depletion may lead to downstream targets for neuroblastoma 
patients with 1p36 deletions. 
 
 
First, I used an in vitro metabolic activity assay to identify neuroblastoma cell lines that 
were either resistant or sensitive to conventional chemotherapy agents. I then used two resistant 
and sensitive cell lines to determine whether Cetuximab could be combined with the 
chemotherapeutic agent irinotecan, a topoisomerase inhibitor, to get a combined anti-
proliferative effect in vitro, as has been tried in a clinical trial with pediatric solid tumors (76).  
Next, I created a model neuroblastoma cell line from the resistant SK-N-AS neuroblastoma 
cell line in which UBE4B levels were depleted in a stable fashion using shRNA. These cells 
were tested by immunoblot for increased protein levels of EGFR. They were then treated with 
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the EGFR-targeted antibody Cetuximab in vitro to study whether growth could be inhibited 
after UBE4B protein depletion. 
High throughput screening was used to identify changes in amounts of other proteins 
as a result of UBE4B depletion. Drug targets for upregulated proteins were then investigated 
based on published pre-clinical and clinical data from other cancers. The two proteins selected 
for further interrogation were the EGFR and STAT5a, a signal transducing protein involved in 
EGFR-mediated signaling. I then used in vitro experiments to study whether the model 
neuroblastoma cells depleted of UBE4B became more sensitive to a STAT5 inhibitor by itself 
or in combination with the EGFR-inhibiting antibody Cetuximab. In addition, in vitro 
experiments to study the effect of these agents on the amount of neuroblastoma cell migration 
and apoptosis were performed. 
The results reported here show that a model neuroblastoma cell line containing low 
levels of UBE4B has elevated amounts of EGFR and STAT5a, which makes it sensitive to 
growth inhibition by EGFR- and STAT5-targeted drug agents. This approach for inhibiting 
neuroblastoma’s growth may be effective for the one-third of neuroblastoma patients who have 
a 1p36 depletion leading to lower levels of UBE4B in their tumors. 
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CHAPTER 2 – Materials and Methods  
 
2.1 Tissue Culture 
 
The SK-N-AS, SK-N-BE(2), CHP134, LAN5, CHLA20, and SK-N-SH human 
neuroblastoma cell lines used in this study have been previously utilized and described by our 
laboratory (87). Cells were cultured in RPMI media (Corning Life Sciences, Tweksbury, MA) 
supplemented with 10% fetal bovine serum and 1% L-glutamine. TLA-HEK293T cells used 
for lentivirus production (Thermo Fisher Scientific, Waltham, MA) were cultured in DMEM 
with 10% fetal bovine serum at 37°C with 5% CO2 and passaged to maintain 20-80% 
confluence. 
 
2.2 Chemotherapy Agents 
 
The chemotherapy agents topotecan, irinotecan, doxorubicin, temozolomide, and 
cisplatin were obtained from Sigma (St. Louis, MO).  Topotecan was dissolved in PBS to make 
a 0.5 mM stock, irinotecan was dissolved in DMSO (Sigma) to make a 50 mM stock, 
doxorubicin was dissolved in PBS to make a 6.9 mM stock, temozolomide was dissolved in 
DMSO to make a 50 mM stock, and cisplatin was dissolved in PBS to make a 3 mM stock. 
Cetuximab (Erbitux, Eli Lilly, Indianapolis, IN) with a stock concentration of 2 mg/mL was a 
generous gift of the University of Texas MD Anderson Cancer Center pharmacy. The STAT5 
inhibitor SH-4-54 (ApexBio Technology, Houston, TX) was purchased as a 10 mM stock 
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solution in DMSO. Drug dilutions for experiments were prepared in cell culture media from 
these stocks just prior to cell treatment. 
 
2.3 Lentiviral Depletion of UBE4B in Neuroblastoma Cells 
 
UBE4B-shRNA was obtained from Sigma’s Mission shRNA library. See table for 
sequences (Table 1). Lentiviral packaging plasmids pMD2.g, pRSV-Rev, and pMDLg/pRRE, 
and scrambled shRNA sequences were a gift of Dr. Sara Prijic (UTHealth McGovern Medical 
School, Houston, TX). Plasmid DNA was purified (Qiagen, Germantown, MD) and 
Lipofectamine 3000 (Thermo Fisher Scientific) was used to transfect HEK 293T cells (60% 
confluent at the time of transfection) using the following amounts of DNA in each reaction: 
2.24 µg shDNA or shScrambled, 5.6 µg pMDLg/pRRE, 2.8 µg pRSV-Rev, and 3.36 µg 
pMD2.g. Twenty four hours following HEK 293T cell  transfection, the media was changed to 
normal media and cells were incubated for an additional 48 hrs. After 48 hours, supernatant 
was collect to obtain virus.  Target neuroblastoma cells were plated at 80% confluence and 
infected using the viral-rich media that had been mixed with 1 μg polybrene (Sigma) per 1 mL 
of media and filtered through a 0.45-micron PVDF membrane (Thermo Fisher Scientific). The 
filtered virus was incubated at room temperature for 10 min and transferred onto the target 
cells. The target cells were incubated overnight with virus, after which the media was changed 
to virus-free media. Two days after infection, the media was supplemented with 1 μg 
puromycin per 1 mL of media to select for infected cells. Cells were selected until untreated 
control cells completed died, which typically took approximately 4 days. A Western blot was 
used to confirm UBE4B levels. 
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Sigma ID # UBE4B shDNA Sequence 
TRCN0000338295 CCGGGCCTAGTTGCCGTCGCTATATCTCGAGATA 
TAGCGACGGCAACTAGGCTTTTTG 
TRCN0000007548 CCGGGCAGGGATCAAATCCACAATACTCGAGT 
ATTGTGGATTTGATCCCTGCTTTTT 
TRCN0000350907 CCGGGCAGGGATCAAATCCACAATACTCGAGTA 
TTGTGGATTTGATCCCTGCTTTTTG 
TRCN0000338354 CCGGGAAGTGTTCAAGCAGATATTTCTCGAGAA 
ATATCTGCTTGAACACTTCTTTTTG 
Table 1. shDNA sequences used for depleting UBE4B in neuroblastoma cell lines. 
 
2.4 Western Protein Blotting 
 
Cell pellets were collected by scraping cells or using 5 mM EDTA (Millipore Sigma, 
Billerica, MA) to release them from their culture dishes. Cells were centrifuged at 1500 x g for 
10 min, resuspended in a small volume of RIPA (1% Triton X-100, 6.1% SDS, 150 mM NaCl, 
50 mM Tris-HCl pH 8.0, 1% NP-40) buffer with a protease inhibitor cocktail (10 mM 
leupeptin, 1 µg/µL pepstatin, 0.3 mM aprotinin, and 1.74 µg/µL PMSF), lysed using sonication 
(5 pulses of 1 second at output control 3, Branson Sonifier 250, VWR Scientific), and 
centrifuged at 2000 x g to separate membranes from cytosolic protein. Lysate was kept on ice 
throughout the lysis process. The amount of protein in each sample was quantified (BCA 
protein assay, Thermo Fisher, Walham, MA) according to the manufacturer’s instructions. 
Samples of lysate (20 μg) were mixed with 6x loading buffer (50 mM Tris-HCl at pH 6.8, 4% 
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SDS, 60% glycerol, 0.6% bromophenol blue, and 30% ß-mercaptoethanol), boiled for 5 min 
at 100°C, and separated using polyacrylamide gel electrophoresis (SDS-PAGE, 5% stacking, 
10% separating).  Proteins were transferred to nitrocellulose membranes in a buffer of tris, 
glycine, and methanol (100 V and 500 mAmp) for an hour. The resultant membrane was 
stained with Ponceau S (Sigma). Next the blot was blocked for an hour at room temperature 
with either BSA (1% in PBS) or nonfat dried milk (5% in PBS), depending on the antibody. 
The blots were incubated overnight at 4°C with either anti-actin antibody (Sigma, A2066), 
anti-UBE4B antibody (Abcam), anti-EGFR antibody (Invitrogen, Carlsbad, CA), or anti-
STAT5 antibody (Cell Signaling, Danvers, MA). Membranes were subsequently washed three 
times with PBS-T and then incubated in a goat anti-rabbit secondary antibody (1:5000 for 
EGFR, 1:2000 for UBE4B, 1:5000 for actin, and 1:2000 for STAT5). Membranes were washed 
three times and developed using chemiluminescence (SuperSignal West Pico, Thermo Fischer 
Scientific) and visualized using x-ray film.  
 
2.5 MTT (MethylThiazolyldiphenyl-Tetrazolium bromide) Cell Metabolic Activity Assays 
 
Human neuroblastoma cells were diluted 1:1 with trypan blue and counted with the 
Countess automated cell counter (Invitrogen, Carlsbad, CA). Cells were then diluted in RPMI 
media to enable plating 7.5e3 cells per well on a 96-well plate with a multichannel pipette and 
incubated for 24 hours to allow adherence. On the second day, the media from each well was 
aspirated and replace with 100 µL of complete RPMI media containing either a chemotherapy 
agent or the appropriate vehicle. For experiments where only a 72-hour time point was taken, 
the treated cells were incubated for three days at 37°C with 5% CO2. In experiments involving 
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Cetuximab, the drug was added fresh to the cells daily. For experiments involving daily 
measurements, cells were plated in three sets so that daily MTT assays could be performed. 
MTT measures mitochondrial metabolic activity and is a surrogate measure for cell viability 
in response to a drug challenge. A stock solution of 5 mg/mL MTT (Sigma) in PBS was first 
prepared and 10 µL of MTT were added to each 100 µL of media (final concentration 0.5 
mg/mL). The plate was protected from light and incubated for 4 hours prior to removal of the 
media and non-reduced MTT, and 100 µL of DMSO was added to each well, incubated for a 
further 10 min, and the absorbance (560 nm) of each well was measured. The background 
absorbance of media only with the MTT reagent was measured and subtracted. Samples 
assessed at 72 hours only were compared to the absorbance of control-treated cells. Samples 
assessed daily were compared to the absorbance of cells at Day 0 before a drug or inhibitor 
was added.  The significance of drug treatments in depletion cells was assessed with a two-
way ANOVA using a Dunnett's multiple comparisons test. All statistical analysis was 
performed with GraphPad Prism software version 7 (La Jolla, CA).  
 For the IC50 growth inhibition experiments in Figure 6, we first assessed the literature 
for a published IC50 values for our model neuroblastoma cell lines and chemotherapy agents. 
We examined the concentrations of selected chemotherapeutics required to inhibit the 
proliferation of various neuroblastoma cell lines. Calculation of IC50 values was done using a 
Boltzmann best fit regression. Only data with a Pearson correlation coefficient > 0.8 and at 
least three cell viability measurements between 20% and 80% were used for analysis. 
Significance of the IC50 results was assessed with a one-way ANOVA with a Tukey multiple 
comparison test.  
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2.6 Cleaved Caspase Assay 
 
Wild type, scrambled, and shUBE4B SK-N-AS cells were counted with the Countess 
automated cell counter and then plated at a density of 4e5 cells in 96-well plates and allowed 
to adhere overnight. On the second day, the media was aspirated from these cells and replaced 
with 100 µL of media alone, media with 5 μM SH-4-54, media with 2 μM Cetuximab, or media 
containing a combination of 5 μM SH-4-54 and 2 μM Cetuximab. CellEvent Caspase 3/7 
Green Detection Reagent (Invitrogen, Carlsbad, CA) was added to the media of all four 
treatment groups at a final concentration of 3 μM, and the cells were incubated for 48 hrs at 
37°C with 5% CO2 protected from light. Next, the cells were imaged using first phase contrast 
microscopy and then florescent microscopy using a GFP filter. The percentage of green-
fluorescing cells to total cells was then calculated. Significance between treatment groups was 
determined with a two-way ANOVA with a Dunnett multiple comparison test using GraphPad 
Prism. 
 
2.7 Transwell Migration Assay 
 
Cells were seeded in six well plates at a density of 3e5 cells per well and incubated 
overnight at 37°C with 5% CO2 to adhere. On Day 2, the cells were treated vehicle (DMSO and 
PBS) and media alone, media with 5 μM SH-4-54, media with 2 μM Cetuximab, or media 
containing a combination of 5 μM SH-4-54 and 2 μM Cetuximab. The cells were incubated 
for an additional 24 hours. On the third day, the cells were separated from the dish with trypsin 
and counted using the Countess automated cell counter. Next, EGF was added to RPMI for a 
24 
 
concentration of 100 ng/mL, and 750 μL was added to wells of a 12 well plate. Falcon Cell 
Culture inserts (Corning Life Sciences, Tweksbury, MA) with 8 μM pores were submerged in 
the wells. Finally, 1.5e5 of the pre-treated SK-N-AS cells were diluted in serum-free RPMI 
media and added to the cell culture insert. The number of cells added was based on the number 
of viable cells from the Countess cell counting procedure so that an equal number of living 
cells was added to each insert. The cells were allowed to incubate overnight 37°C with 5% 
CO2.   
The following day the cells were washed and fixed for microscopy. First, the non-
invading cells were scrubbed from the top surface of the membrane using a cotton-tipped swab 
moistened with media for the first scrub and PBS for the second scrub. Next, the membranes 
were fixed with 100% methanol for 5 min. The membranes were then rinsed in water for 1 min 
and stained with a 1 μg/mL DAPI in PBS with 0.1% Tween for 20 min at room temperature 
protected from light. The membranes were then washed again in water for 1 min and inverted 
to dry in room air. Lastly, a fine-tipped scalpel was used to cut the membranes from the insert. 
The membranes were place bottom-side-up on a glass microscope slide. FluroSave reagent 
(Millipore Sigma, Billerica, MA) was added dropwise to the membranes. They were then 
covered with glass coverslips and then sealed with nail polish.  
The glass slides were protected from light in the fridge at 4°C. The membranes were 
later imaged with 10x magnification on a fluorescent microscope. The instrument was set for 
DAPI with an excitation wavelength of 358 nm and an emission wavelength of 461 nm. Four 
10x fields on each membrane were counted, and then the average was taken per condition to 
compute the number of cells per high powered field (HPF). The experiment was performed in 
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triplicate and significance was determined with a two-way ANOVA with a Dunnett multiple 
comparison test using GraphPad Prism. 
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CHAPTER 3 – Characterization of Antiproliferative Response to Chemotherapy in 
Neuroblastoma 
 
3.1 Rationale 
 
We wanted to identify an appropriate model neuroblastoma cell line that would be 
resistant to chemotherapy treatment in vitro. This line would become the model for future 
experiments where UBE4B was depleted. We studied the growth inhibitory effect of five 
conventional chemotherapy agents and Cetuximab, a monoclonal antibody that specifically 
targets the EGFR, toward seven neuroblastoma cell lines in vitro. Given the different molecular 
profiles of these lines, it was not clear how each would respond to an in vitro chemotherapy 
challenge. We wanted to identify lines that were especially resistant or sensitive to 
chemotherapy in order to select a resistant line for later experiments. We also wanted to use a 
cell line with a 1p deletion and possibly higher levels of EGFR to assess whether Cetuximab 
combined with a conventional agent that targets cell division might be able to inhibit 
neuroblastoma’s growth. 
 
 
3.2 SK-N-AS and SK-N-BE(2) are Resistant and LAN5 and CHP134 are Sensitive 
Neuroblastoma Cell Lines 
 
The relative sensitivity or resistance of commonly used neuroblastoma cell lines to 
chemotherapeutics has been previously described (88), however, cross-lab variability because 
of cell passage number, culture conditions, drug formulation variability, and assay variability 
27 
 
can affect these results (89). Therefore, we first examined the sensitivity of seven 
neuroblastoma cell lines (Table 2) to five chemotherapeutics in MTT cell metabolic activity 
assays. The IC50 (concentration of drug that inhibits proliferation by 50%) was calculated for 
each drug in each cell line. SK-N-AS and SK-N-BE(2) cell lines were the most resistant, and 
LAN5 and CHP134 cells lines were the most sensitive to chemotherapeutics (Figure 6). With 
the exception of doxorubicin, the IC50 for SK-N-AS was significantly higher for each 
chemotherapy drug when compared with many of the other cell lines tested. 
 
 
Table 2. Molecular characteristics of the neuroblastoma cell lines used in this 
study. 
 
All cell lines except SK-N-SH had either a 1p deletion or translocation. The 1p36 site 
specifically is the location of UBE4B. Additionally, the lines NGP, CHP-134, LAN5, 
and SK-N-BE(2) had N-myc amplifications which are a bad prognostic indicator in 
patients. Finally, the lines SK-N-AS, CHLA-20, and SK-N-BE(2) have been 
described in the literature as being resistant (R), while CHP-134 has been described 
as sensitive (88). 
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Figure 6. IC50s of model neuroblastoma cells lines to chemotherapy agents  
The inhibitory concentration required for 50% inhibition of proliferation (IC50) in vitro 
at 72 hours varies across seven neuroblastoma cell lines using five chemotherapy 
agents with varying mechanisms of action. We identified SK-N-AS as being more 
resistant because these cells required higher concentrations of chemotherapeutics for 
inhibition with all drugs except cisplatin. We identified LAN5 and CHP134 as more 
sensitive cell lines because lower drug doses were needs to inhibit proliferation. 
Graphs show the average of at least three independent trials + the SD.  
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3.3 Cetuximab and Irinotecan Combination Treatment Increases the Efficacy of Low Doses of 
Irinotecan   
 
EGFR has been reported to be overexpressed in proliferating neuroblastoma, especially 
resistant lines taken from relapsed patients (1). After establishing the resistant and sensitive 
cell lines in our panel, we next studied whether Cetuximab, a monoclonal antibody that 
specifically targets EGFR, in combination with irinotecan, which interferes with DNA 
replication, would inhibit proliferation. Cetuximab has had limited efficacy toward 
neuroblastoma in patients (76, 90), but there is sparse in vitro data published to describe the 
response of neuroblastomas to the anti-proliferative effect of Cetuximab. EGFR has been 
reported to be elevated in resistant neuroblastomas (1, 2), so we examined whether this 
combination of Cetuximab and irinotecan would be effective in the resistant lines SK-N-AS 
and SK-N-BE(2) when compared with the more sensitive LAN5 and CHP134. The results 
showed no significant change in the IC50s between irinotecan monotherapy and combination 
therapy at 72 hours (Figure 7). However, the combination did significantly improve the 
efficacy of low doses of irinotecan in all lines except SK-N-BE(2). Cetuximab alone did not 
have much of an effect on proliferation and neither did the lowest dose of irinotecan, but the 
combination showed a significant change (Figure 8). This suggests that Cetuximab may not be 
effective at inhibiting growth of wild type cells, but it can enhance the cytotoxic efficacy of 
low concentrations of irinotecan. 
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Figure 7. Combined treatment of wild type SK-N-AS can increase the anti-
proliferative efficacy of low concentrations of irinotecan when measured at 72 
hours. 
 
Cetuximab was combined with increasing concentrations of irinotecan to test for 
synergy between the two agents in two resistant lines SK-N-AS, SK-N-BE(2) (a, b) 
and two sensitive lines LAN5, CHP134 (c, d). Proliferation was assessed at 72 hours 
using an MTT assay for mitochondrial activity. 
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Figure 8. Comparison of low dose irinotecan combined with Cetuximab 
sensitive and resistant neuroblastoma cell lines 
 
In a post-hoc analysis, the effectiveness of the lowest concentration of irinotecan was 
compared with Cetuximab and the combination of both drugs for each cell line (a - 
d) revealing that while the IC50 did not appreciably change, the efficacy of lower 
irinotecan doses did increase when combined with Cetuximab. All graphs represent 
the means + standard deviation of at least three independent trials. 
 
3.4 Conclusions 
These experiments indicate that of all the neuroblastoma cell lines tested, SK-N-AS 
and SK-N-BE(2) are two of the most resistant lines to the five chemotherapy agents examined. 
This was one reason for selecting SK-N-AS for future experiments of this study as a model 
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cell line that is resistant to treatment. In addition, it does not appear that the addition of 
Cetuximab, an EGFR inhibitor, significantly changes the IC50 for irinotecan in the four cell 
lines that were tested in vitro, although addition of Cetuximab to irinotecan did appear to 
enhance the growth inhibitory effect of low doses of irinotecan. 
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CHAPTER 4 – Anti-proliferative Effect of EGFR Targeted Therapy 
 
4.1 Rationale 
 
We wanted to study whether a depletion of UBE4B levels in a treatment resistant 
neuroblastoma cell line could make them more sensitive to growth inhibition with a drug agent 
that targets EGFR. Transient UBE4B depletion (53) results in a two-fold increase in the levels 
of EGFR in HeLa cells.  Neuroblastoma cells overexpressing UBE4B were less sensitive to 
the anti-proliferative effects of Cetuximab (18).  Our hypothesis was that stable depletion of 
UBE4B levels in a model neuroblastoma cell line would increase EGFR levels. This would 
introduce more targets to binding of the EGFR-targeted antibody Cetuximab and make those 
cells prone to growth inhibition by Cetuximab. 
 
4.2 Depletion of UBE4B in SK-N-AS Leads to Increased EGFR Levels and Increased Anti-
Proliferative Response to Cetuximab 
 
Since UBE4B promotes the degradation of the EGFR (53), we hypothesized that 
resistant neuroblastoma cells depleted of UBE4B might become more sensitive to EGFR 
inhibition. UBE4B was depleted in SK-N-AS cells using a lentiviral-delivered shRNA against 
UBE4B followed by antibiotic selection. After one week of selection, we observed nearly 
undetectable levels of UBE4B in SK-N-AS cells (Figure 9). Since EGFR levels and 
downstream MAPK/ERK signaling are regulated by UBE4B (19, 53), we examined EGFR 
levels in the UBE4B-depleted SK-N-AS cells and observed a two-fold increase in EGFR levels 
(Figure 9), similar to what we have previously observed after acute depletion (53). Increased 
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EGFR levels promote cell proliferation in neuroblastoma (2) and lead to poor patient outcomes 
(18, 91). We hypothesized that elevated EGFR expression would enable anti-EGFR antibody 
(66) therapeutic efficacy. Treatment with increasing concentrations of Cetuximab significantly 
inhibited the proliferation of UBE4B-depleted SK-N-AS cells but did not inhibit the 
proliferation of parental cells (Figure 10). These data suggest that the elevated EGFR levels 
produced by UBE4B depletion may provide additional targets for Cetuximab allowing the drug 
to inhibit proliferation. 
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Figure 9. Western blot and quantitation of UBE4B depletion and subsequent 
change to EGFR in neuroblastoma SK-N-AS with stable UBE4B expression 
 
Depletion of UBE4B to undetectable levels using shRNA in the SK-N-AS 
neuroblastoma cell line leads to a two-fold increase in EGFR. Quantifications in are 
the averages of three independent trials + the SD. 
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Figure 10. Growth inhibitory response to the EGFR-targeted antibody 
Cetuximab in neuroblastoma SK-N-AS with stable UBE4B expression 
 
Treatment of model SK-N-AS neuroblastoma cells bearing a stable depletion of 
UBE4B (shUBE4B) with 1 𝜇𝑀 and 2 𝜇𝑀 of Cetuximab, a drug specific to EGFR, led 
to a significant drop in growth over 72 hours as measured by an MTT assay.  
 
 
4.3 Conclusions 
 
These experiments demonstrated that it is possible to deplete UBE4B to undetectable 
levels using a lentiviral shRNA delivery system resulting in a concurrent two-fold increase in 
EGFR protein levels. In vitro MTT assays revealed that Cetuximab (1 and 2 µM) can 
significantly inhibit the growth of UBE4B-depleted SK-N-AS cells a decrease not observed in 
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parental cells or those transduced with a scrambled shRNA suggesting that the change in 
response is a result of UBE4B depletion. 
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CHAPTER 5 – Downstream Protein Changes as a Result of UBE4B Depletion 
 
5.1 Rationale 
 
There is an inverse correlation between UBE4B and EGFR levels in neuroblastoma 
(18, 19, 53). The increase in EGFR levels that occurs following transient UBE4B depletion 
may result from decreased ubiquitination of EGFR resulting in decreased EGFR degradation. 
We examined whether other proteins might be increased or decreased in amount as a result of 
UBE4B depletion. We stably depleted SK-N-AS cells and assessed lysates using the Reverse 
Phase Protein Array (RPPA) method in which the levels of 305 cancer-related proteins were 
examined.   
 
5.2 Depletion of UBE4B Leads to a Two-fold Increase in STAT5a  
 
We observed 57 proteins to be increased by two-fold or more (Figure 11a) and 26 
proteins decreased by 50% or more (Figure 11b). RPPA analysis confirmed a two-fold increase 
in EGFR, consistent with our data (Figure 9) and earlier studies (53). Among the proteins that 
were increased in amount, there was a mixture of proteins involved in proliferation and growth 
inhibition (Table 3). Among the proteins that were decreased in amount, many were pro-
proliferative in nature (Table 4). We confirmed these increases in STAT5a protein levels using 
immunoblotting (Figure 12), and we found that it remained increased two-fold. These data 
suggest that EGFR and STAT5a levels increased specifically because of UBE4B protein 
depletion in the model SK-N-AS neuroblastoma cell line. 
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Figure 11. Reverse Phase Protein Analysis (RPPA) of increased and decreased 
proteins subsequent to UBE4B depletion in neuroblastoma SK-N-AS 
 
Reverse phase protein analysis was used to assay 305 proteins increased or decreased 
in amount as a result of a UBE4B depletion the neuroblastoma SK-N-AS. This subset 
of that data shows proteins that are either increased two-fold or more (a) or decreased 
50% or more (b) relative to the wild type and scrambled versions of that cell line. 
The red arrows indicate EGFR and STAT5a, the two proteins that were studied here. 
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Protein Description Pathway Function 
14-3-3-𝜁 Promotes cell proliferation, adhesion and survival, and it inhibits apoptosis in multiple cancers. (92)  Anti-apoptosis 
BiP-
GRP78 
Endoplasmic reticulum chaperone protein necessary 
for cancer survival (93)  
Anti-
apoptosis 
p27-Kip-1 
Negative regulator of apoptosis; not regulated by 
MYCN in neuroblastoma (94)  
Anti-
apoptosis 
Bid 
Promotes apoptosis and can be used for survival 
prediction in colon cancer (95)  Apoptosis 
Bim Induces apoptosis and anoikis (96)  Apoptosis 
PEA-15 Positive regulation of apoptosis (97) 
AKT/PKB, 
blocks 𝛽-
catenin Apoptosis 
Atg3 
E2-like enzyme that is essential for promoting 
autophagy. It is degraded in the presence of 
chemotherapy agents like etoposide (98)  Autophagy 
WIPI1 
Also known as ATG18 and it promotes autophagy 
(99)  Autophagy 
CD171 
Cell adhesion marker that has characteristic 
expression in many cancers (100)  Cell adhesion 
CD44 
Mediates cell-cell and cell-matrix adhesion and is 
expressed in tumors that are epithelial in origin. It 
can be used as a prognostic marker. (101)  Cell adhesion 
Collagen-
VI 
Cell adhesion protein that is highly expressed in a 
number of cancers (102)  Cell adhesion 
E-cadherin 
Calcium-dependent adhesion molecule. Its 
dysregulation leads to tumor progression (103)  Cell adhesion 
N-
Cadherin 
Calcium-dependent adhesion molecule that is 
elevated in amounts in tumor tissues (104)  Cell adhesion 
Stat5a 
Signal transduction and activation of transcription 
(STAT) is activated by EGFR. (105) Jak/STAT Cell signaling 
Box 
Subunit of an E3 ubiquitin ligase. Its dysregulation 
leads to human malignancy. (106) JNK E3 ligase 
4E-BP1 
Mediates the regulation of protein translation by 
hormones, growth factors, and other stimuli that 
signal through the MAPK and AKT pathways. Loss 
of 4E-BP1 function induces epithelial-mesenchymal 
transition (EMT) and increases metastatic capability 
of cancer cells by translational activation of Snail. 
(107) 
AKT and 
MAPK/ERK Metastasis 
EMA 
Epithelial membrane antigen is a glycoprotein and 
its altered distribution in cells in a prognostic marker 
in breast cancer. (108)  Metastasis 
TWIST Transcriptional regulator of cell migration (109)  Migration 
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NDRG1 
_pT346 
Stress-responsive protein involved in hormone 
responses, cell growth, and differentiation (110)  
Migration 
inhibitor 
YB1_pS10
2 
Y-Box protein 1 mediates pre-mRNA alternative 
splicing regulation. It is a promoter of proliferation 
(111)  Proliferation 
CD29 
Integrin protein that is marker of metastasis in breast 
cancer (112)  Pro-migration 
Hes1 
Transcriptional repressor that is involved in cell 
migration by promoting epithelial mesenchymal 
transition (EMT). It mediates crosstalk between 
Jak/STAT and Notch signaling through Stat3. (113) 
Jak/STAT, 
Notch Pro-migration 
MMP2 
Matrix metalloproteinase-2 promotes cell 
migration(114)  Pro-migration 
VHL-
EPPK1 
Epiplakin 1 (EPPK1) is a cytoskeletal linker protein 
that connects to intermediate filaments and controls 
their reorganization in response to stress (115)  Pro-migration 
Vimentin 
Intermediate filament that is overexpressed in 
epithelial cancers (116) SMAD Pro-migration 
Cox-IV 
Cytochrome oxidase that has elevated levels in 
colorectal cancer (117)  Proliferation 
Cyclophili
n-F 
Accelerates folding of proteins and counteracts p53 
regulation of cancer growth (118)  Proliferation 
EGFR 
Growth factor receptor that is increased in amount in 
many cancers (119) 
AKT/PI3K, 
MAPK/ERK, 
Jak/STAT Proliferation 
Histone-H3 
The H3 variant of histones, which are involved in 
transcription regulation, DNA repair, DNA 
replication and chromosomal stability, has been 
shown to common in malignant pediatric brain 
cancers. (120)  Proliferation 
IGFBP2 
IGF binding protein 2 inhibition has been shown to 
limit tumor proliferation. It potentiates EGFR-
STAT3 signaling. (121),(122) STAT Proliferation 
MIF 
Macrophage migration inhibitory factor is 
implicated in the tumorigenesis, angiogenesis, and 
metastasis of many cancer phenotypes (123) 
MAPK/ERK, 
AKT/PI3K Proliferation 
MSI2 
RNA binding protein that promotes TGF-𝛽 
signaling and non-squamous cell lung cancer 
metastasis (124) TGF-	𝛽 Proliferation 
PI3K-
p110-a 
This is a specific mutation in Phosphoinositide-3-
kinase (PI3K) signaling. PI3K/AKT Proliferation 
PRAS40_p
T246 
Proline-rich AKT substrate and subunit of 
mTORC1, which regulates cell growth and survival 
in response to nutrient and hormonal signals. (125) PI3K/AKT Proliferation 
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TFAM 
Binds to the mitochondrial light strand promoter and 
functions in mitochondrial transcription regulation. 
Its  knockdown lessens proliferation (109)  Proliferation 
Stathmin-1 
Microtubule destabilizer that plays an important role 
in cell cycle progression, segregation of 
chromosomes, clonogenicity, cell motility and 
survival. Its overexpression has been reported in 
malignant hematopoietic cells. (126)  Proliferation  
DJ1 
Negative regulator of apoptosis and that increases 
breast cancer cell invasion. (127) AKT/PKB 
Proliferation 
and anti-
apoptosis 
Cox2 
Highly expressed in many cancers. It converts 
prostaglandin H2 to make PGE2 and promotes 
proliferation and apoptosis (128)  
Proliferation 
and apoptosis 
IGFRb 
Receptor tyrosine kinase which mediates the 
pleiotropic actions of insulin (129) MAPK, PKB 
Proliferative 
receptor 
Insulin 
receptor 𝛽signaling Insulin receptor 𝛽 signaling may be highly stimulated and therefore targeted in certain cancers. (130) MAPK/ERK, AKT/PI3K Proliferative receptor 
Creb 
Nuclear transcription factor that mediates response 
to growth factors. It is involved in tumor initiation, 
progression and metastasis. (131) AKT/PKB 
Proto-
oncogene 
ENY2 
Coordinates activity of deubiquitinating enzymes 
and its dysregulation can promote cancer (132)  
Proto-
oncogene 
MERIT40_
pS29 
Part of the BRCA-1 complex. Its activation through 
phosphorylation mediates DNA repair after cancer 
treatment with doxorubicin. (133) AKT 
Resistance 
mediator 
14-3-3-𝛽 Blocks the nuclear translocation of the phosphorylated form (by AKT1) of SRPK2. It is a tumor suppressor. (134) MAPK/ERK, Hippo Tumor suppressor 
53BP1 
Involved in cell cycle checkpoint and DNA repair 
activities. It is a known tumor suppressor in breast 
cancer. (135)  
Tumor 
suppressor 
p16INK4a 
Negative regulator of proliferation and acts as a 
tumor suppressor (136)  
Tumor 
suppressor 
Pdcd4 
Inhibits translation initiation and cap-dependent 
translation and functions as a tumor suppressor 
(137)  
Tumor 
suppressor 
Smad4 
Tumor suppressor that may be inactivated in many 
cancers (138) TGF-𝛽 Tumor suppressor 
SOD2 
The superoxide dismutase 2 destroys superoxide 
radicals. Polymorphisms may increase cancer risk. 
(139)  
tumor 
suppressor 
TAZ Restricts proliferation and promotes apoptosis (140) 
Hippo & 
Wnt 
Tumor 
suppressor 
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UBAC1 
E3 ligase that causes proteasome-mediated 
degradation of NF-κB. It is also known as KPC1. 
(141) E3 ligase 
Tumor 
suppressor 
YAP_pS12
7 
Restricts proliferation and promotes apoptosis. It 
overlaps with TAZ (140) 
Hippo & 
Wnt 
Tumor 
suppressor 
Caveolin-1 
May act as a scaffolding protein within caveolar 
membranes and is associated with tumor 
progression. Depletion leads to altered Jak/STAT, 
JNK, and Src signaling. (142) 
Jak/STAT, 
JNK, Src Tumorigenic 
eIF4E 
Translation initiation factor. Its phosphorylation 
promotes tumorigenesis. (143) 
MAPK and 
AKT/PI3K Tumorigenic 
eIF4E_ 
pS209 Phosphorylation site for eIF4E (143) 
MAPK and 
AKT/PI3K Tumorigenic 
PAI-1 
Plasminogen activator inhibitor 1 is a negative 
regulator of cell adhesion. It has a pro-tumorigenic 
role in cancer by promoting angiogenesis and tumor 
cell survival. (144)  Tumorigenic 
PKC-𝛿 
_pS664 
Calcium-independent, phospholipid- and 
diacylglycerol (DAG)-dependent serine/threonine-
protein kinase. This mutation promotes 
tumorigenesis in pancreatic cancer. (145) PKC 
Tumorigenic 
(when 
mutated) 
 
Table 3. Description of proteins increased two-fold or more subsequent to 
UBE4B depletion in neuroblastoma SK-N-AS 
 
The proteins that were elevated two-fold or more in the RPPA analysis of SK-N-AS 
cells depleted of UBE4B were analyzed to determine their role in the cell and 
associations with known signaling pathways. 
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Protein Description Pathway Function 
AMPK𝛼 
Catalytic subunit of AMP-activated protein 
kinase (AMPK). Regulates cellular metabolism 
and is associated with cell growth, metabolism, 
and autophagy. Downregulation in gastric 
cancer is associated with poor prognosis. (146) AMPK Autophagy  
Cyclin-B1 
Essential for the control of the cell cycle at the 
G2/M (mitosis) transition. High levels are 
associated with poor prognosis in breast cancer. 
(147)   
Cell cycle 
regulator  
PLK1 
Serine/threonine-protein kinase and positive 
regulation of ubiquitin protein ligase activity. 
(148)   
Cell division 
regulator 
DUSP4 
Regulates mitogenic signal transduction by 
dephosphorylating both threonine and tyrosine 
residues on the MAP kinases ERK1 and ERK2. 
(149) MAPK/ERK Cell signaling 
Raptor 
Regulates mTORC1 activity. Upregulation 
makes cells less sensitive to PI3K/AKT 
pathway inhibition (150). PI3K/AKT Cell signaling 
mTOR 
Serine/threonine protein kinase which is a 
central regulator of cellular metabolism, growth 
and survival (151). PI3K/AKT Cell signaling 
PKCa 
Calcium-activated, phospholipid- and 
diacylglycerol (DAG)-dependent 
serine/threonine-protein kinase important in cell 
signaling.  (152) PKC 
Cell signaling, 
pro-proliferation 
BAP1 
Specifically mediates deubiquitation of histone 
H2A and regulates cell growth. (153)   
Deubiquitation 
and tumor 
suppressor 
ADAR1 
Catalyzes the hydrolytic deamination of 
adenosine to inosine in double-stranded RNA 
(dsRNA). This is referred to as A-to-I RNA 
editing. It is associated with tumor-infiltrative 
lymphocytes in triple negative breast cancer. 
(154)   Pro-migration 
Rictor 
Subunit of mTORC2 that functions upstream of 
Rho GTPases to enhance cell migration. 
Overexpression yields poor prognosis in colon 
cancer. (155) PI3K/AKT Pro-migration 
TRIM25 
E3 ubiquitin ligase that enhances cell growth 
and proliferation in cancer by modulating p53 
signaling. (156)  
Pro-proliferation; 
E3 ubiquitin 
ligase 
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A-Raf 
Isoform of Raf which is involved in cancer 
proliferation, migration, and invasion through 
involvement in the MAPK pathway. (157) MAPK/ERK Pro-proliferation 
eIF4G 
Commonly found in breast cancer and increases 
translation for proteins required for 
proliferation and survival (158)   Pro-proliferation 
S6 
Ribosomal protein that regulates cell growth 
and proliferation. Reduced phosphorylation can 
increase sensitivity to MEK inhibition. (159) PI3K/AKT Pro-proliferation 
Src_pY527 
Non-receptor protein tyrosine kinase that is 
involved in the regulation of cell growth and 
survival, apoptosis, cell-cell adhesion, 
cytoskeleton remodeling, and differentiation. 
Overexpressed in a number of human cancers. 
(160)   Pro-proliferation 
Stat3 
Signal transducer and transcription activator 
that mediates cellular responses to interleukins, 
KITLG/SCF, LEP and other growth factors. 
(161)   Pro-proliferation 
TFRC 
Cellular uptake of iron occurs via receptor-
mediated endocytosis of this ligand-occupied 
transferrin receptor into specialized endosomes. 
Promotes proliferation when overexpressed. 
(162)   Pro-proliferation 
FAK_pY397 
Non-receptor protein-tyrosine kinase that plays 
an essential role in regulating cell migration, 
adhesion, spreading, reorganization of the actin 
cytoskeleton, formation and disassembly of 
focal adhesions and cell protrusions, cell cycle 
progression, cell proliferation and apoptosis. 
(163)   
Pro-proliferation 
and migration 𝛽-Catenin Key downstream component of the canonical Wnt signaling pathway. (164) WNT Proto-oncogene 
eEF2 
Tumor-associated antigen that is overexpressed 
in many types of cancer. (165)   Tumor antigen 
PTEN Tumor suppressor (166) PI3K/AKT 
Tumor 
suppressor 
TSC1 
TSC2, inhibits the nutrient-mediated or growth 
factor-stimulated phosphorylation of S6K1 and 
EIF4EBP1 by negatively regulating mTORC1 
signaling. (167) PI3K/AKT 
Tumor 
suppressor 
Tuberin 
TSC2 
In complex with TSC1, this tumor suppressor 
inhibits the nutrient-mediated or growth factor-
stimulated phosphorylation of S6K1 and 
EIF4EBP1 by negatively regulating mTORC1 
signaling. (167) PI3K/AKT 
Tumor 
suppressor 
47 
 
FASN 
Fatty acid synthetase whose overexpression is 
common in many types of cancer. (168)   Tumor marker 
 
Table 4. Description of proteins decreased 50% or more subsequent to UBE4B 
depletion in neuroblastoma SK-N-AS 
 
The proteins that were decreased by 50% or more in the RPPA analysis for SK-N-AS 
cells depleted of UBE4B were analyzed to determine their role in the cell and 
associations with known signaling pathways. 
 
 
 
 
Figure 12. Western blot and quantitation of changes in STAT5 in 
neuroblastoma SK-N-AS with UBE4B depletion 
 
One protein of interest, STAT5a, increased two-fold in the RPPA dataset and this 
increase was then confirmed with quantitative Western immunoblotting. 
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5.3 Conclusions 
 
 I observed that depletion of UBE4B protein in SK-N-AS cells results in increases and 
decreases in the levels of a number of proteins. EGFR and STAT5a levels both increased two-
fold.  These data suggest that that these two pro-proliferative proteins can be targeted 
individually or in combination in order to inhibit the growth of the model neuroblastoma cells 
in vitro.  
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CHAPTER 6 – Growth Inhibitory Effect of Combined EGFR and STAT5 Targeted 
Therapy 
 
6.1 Rationale 
 
We wanted to test whether targeting EGFR and STAT5a pharmacologically could 
inhibit growth of the model SK-N-AS neuroblastoma cell line depleted of UBE4B in vitro. 
The levels of both of these proteins were increased two-fold in the RPPA analysis and 
immunoblot of cell lysates. We also found evidence in the literature of studies that had targeted 
either EGFR (18, 91) or STAT5 (169) in neuroblastoma. Our hypothesis was that dual 
inhibition of both EGFR and STAT5 would reduce growth in vitro and increase apoptotic cell 
death. Dual inhibition might also prevent migration in vitro, which is an early step in metastasis 
(170).  
 
 
6.2 Depletion of UBE4B Enhances the Anti-Proliferative and Pro-Apoptotic Effect of 
Cetuximab and the STAT5 inhibitor SH-4-54  
 
STAT5a is a member of the Jak/STAT signaling pathway that can be activated by 
EGFR (171). STAT5a levels are increased in proliferative cancers, and its constitutive 
activation can contribute to resistance to EGFR-targeted therapies (83). STAT5a has also been 
targeted with chemotherapeutics as either monotherapy or combination therapy in other 
cancers like leukemia (84, 172) and prostate cancer (173). STAT5 is a part of Jak/STAT 
signaling of EGFR (80), and directly inhibiting signaling pathways of EGFR can partially 
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prevent signal transduction even when the EGF ligand is bound (174). Therefore, it may be 
beneficial to specifically target both EGFR and STAT5a to reduce cell proliferation and 
resistance to targeted therapies. We hypothesized that simultaneous inhibition of EGFR and 
STAT5a might be more effective at inhibiting SK-N-AS proliferation than either agent alone. 
The rationale for this was that in some cases signaling would be blocked by competitive 
inhibition of EGF binding because of Cetuximab, whereas in other cases the ligand would still 
bind, but signaling would still be partially inhibited by STAT5 inhibition.  
The combination of a STAT5a inhibitor SH-4-54 (5 𝜇M) with Cetuximab (2 µM) has 
a significant anti-proliferative effect in UBE4B-depleted SK-N-AS neuroblastoma cells 
(Figure 13). This antiproliferative effect was not observed in control cells transfected with a 
scrambled shRNA or in parental cells. These data suggest that combined inhibition of EGFR 
and STAT5a inhibits SK-N-AS cell growth because of the depletion of UBE4B. We saw signs 
of cell detachment and morphology changes in vitro with microscopy when measuring cell 
growth (data not shown). Additionally, the fraction of metabolically viable cells began to 
decrease at 72 hours as measured by MTT assays. These facts suggest that combined 
EGFR/STAT5 inhibition may be producing apoptosis. Moreover, the addition of SH-5-54 
appears to potentiate the effect of Cetuximab (Figure 14). The anti-proliferative effect observed 
with 2 µM Cetuximab is enhanced by the addition of SH-5-54. 
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Figure 13. Anti-proliferative effect of combination EGFR and STAT5 
inhibition in neuroblastoma SK-N-AS with UBE4B depletion. 
 
The proliferation of wild type, scrambled, and UBE4B-depleted SK-N-AS 
neuroblastoma cells was measured in the presence of erlotinib, an EGFR tyrosine 
kinase inhibitor (c), Cetuximab (a), the STAT5 inhibitor SH-4-54 (f), and a 
combination of either the STAT5 inhibitor with erlotinib (d) or STAT5 inhibitor with 
Cetuximab (b) using an MTT mitochondrial activity assay for 72 hours. 
Measurements were taken daily and normalized to day zero, the time when the drugs 
were initially added to cells in vitro. Data points for each graph represent the mean + 
the SD from three independent trials. 
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Figure 14.  Demonstration of potentiation between Cetuximab alone and 
Cetuximab with a STAT5 inhibitor in inhibiting the proliferation of 
neuroblastoma 
 
The combination of 2 µM Cetuximab with 5 µM of SH-4-54, a STAT5 inhibitor, 
shows a potentiation effect (175). Cetuximab alone causes a significant decrease in 
proliferation in model SK-N-AS cells with a stable depletion of UBE4B. STAT5 
inhibition alone does not show a significant anti-proliferative effect. The combination 
of the STAT5 inhibitor SH-4-54 and Cetuximab is greater for all neuroblastoma SK-
N-AS lines that we tested. In the model SK-N-AS line with a stable depletion of 
UBE4B (shUBE4B), there is a significantly greater anti-proliferative effect than in 
the wild type or control cells. 
 
 We next examined whether the combination of Cetuximab and SH-4-54 affected 
apoptosis in UBE4B-depleted cells. UBE4B-depleted SK-N-AS cells, parental cells, or cells 
transfected with a scrambled shRNA were treated with Cetuximab and SH-4-54 alone or in 
combination. We measured the number of cells that were fluorescently labeled indicating 
caspase 3 and 7 activation and calculated the ratio of fluorescently-labeled cells to the total 
number of cells (Figure 15). There was an increase from about 1.5% GFP+ cells (cells treated 
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with vehicle alone) to 5% GFP+ cells (scrambled cells) or 7.5% GFP+ in wild type SK-N-AS 
when they were treated with a combination of Cetuximab and SH-4-54. The model SK-N-AS 
depleted of UBE4B increased significantly from 2.5% GFP+ cells with vehicle treatment to 
nearly 13% with combination treatment. Treatment with SH-4-54 and Cetuximab alone 
showed 4.7% and 5.1% increases, respectively, in cleaved caspases indicating that these agents 
have some toxic effect by themselves. These data suggest that the addition of SH-4-54 
potentiates the antiproliferative effect of Cetuximab in neuroblastoma SK-N-AS cells, causing 
greater cell death than either agent alone. 
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Z 
Figure 15. Pro-apoptotic effect of combination EGFR and STAT5 inhibition in 
neuroblastoma SK-N-AS with UBE4B Depletion 
 
Cetuximab combined with STAT5 inhibition causes apoptotic cell death at 48 hours, 
particularly in cells depleted of UBE4B. Wild type SK-N-AS neuroblastoma cells or 
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SK-N-AS cells with stable expression of a resistance plasmid with a scrambled insert 
or an shUBE4B insert were treated with 5 𝜇𝑀 STAT5 inhibitor, 2 𝜇𝑀of Cetuximab, 
or a combination of the two. (a) Caspase-3/7 activity was assessed with the CellEvent 
green detection reagent and phase contrast microscopy was used to quantify cell 
number. (b) The ratio of green-expressing cells to total number of cells was 
significantly greater in UBE4B depleted cells co-treated with the STAT inhibitor and 
Cetuximab. 
 
 
6.3 Combination Treatment with Cetuximab and the STAT5 Inhibitor SH-4-54 Inhibits Cell 
Migration In Vitro 
 
One of the challenges in treating stage 4 neuroblastoma is that the disease has often 
metastasized prior to diagnosis (7). Cell migration is an initial step in the metastatic process 
(170), that can be assessed in vitro. We have shown that the combination of EGFR and STAT5a 
inhibition reduces growth and increases apoptosis. Since EGFR activation can underlie 
migration (176), we used a transwell migration model to assess whether EGFR and STAT5a 
inhibition might affect tumor cell migration.  
UBE4B-depleted SK-N-AS cells and control cells (parental cells and those transfected 
with a scrambled shRNA) were pre-treated for 24 hours with a combination of Cetuximab (2 
µM) and SH-4-54 (5 µM). We observed that Cetuximab and SH-4-54 slightly decreased 
migration for parental, scrambled, and UBE4B-depleted cells (Figure 16). However, the 
combination of Cetuximab and SH-4-54 significantly reduced transwell migration in UBE4B-
depleted SK-N-AS cells when compared to the effect of the combination in parental and 
scrambled control cells (Figure 16). The effect of the combined inhibitors in the depletion line 
was also significantly less compared to either STAT5 or EGFR inhibition alone. These data 
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suggest that in neuroblastoma cells with low levels of UBE4B, the combination of EGFR and 
STAT5 inhibitors may reduce tumor cell migration. 
 
Figure 16. Anti-migratory effect of combination EGFR and STAT5 inhibition 
in neuroblastoma SK-N-AS with UBE4B Depletion 
 
Migration of UBE4B-depleted SK-N-AS neuroblastoma cells is impaired when 
treated with a combination of the STAT5 inhibitor SH-4-54 and the EGFR inhibitor 
Cetuximab. Cells were pretreated with 24 hours with PBS/DMSO vehicle, the 
STAT5 inhibitor, Cetuximab, or a drug combination mixed in complete media. Cells 
57 
 
were then counted and an equal amount of 1.5e5 viable cells was added to the top 
surface of transwell membranes. Cells were allowed to grow and migrate for 24 
additional hours in the presence of drug at 37°C. Membranes were then washed, 
fixed, and stained with DAPI to visualize migratory cells (a) which were then 
quantified by counting cells visible in a high-power field at 10x magnification and 
averaging at least three fields per condition. The quantitation (b) represents the 
average of three trials + the SD. 
 
 
6.4 Conclusions 
We observed that EGFR and STAT5a inhibitors can produce growth inhibitory effects 
over a three-day time course in UBE4B-depleted SK-N-AS cells. Growth inhibition was 
observed with Cetuximab, but not erlotinib, a tyrosine kinase inhibitor. Addition of a STAT5 
inhibitor potentiated the growth inhibitory effect of Cetuximab. In fact, in vitro experiments 
suggest that the combination of EGFR and STAT5 inhibitors increased apoptotic cell death of 
all cell lines, and impaired cellular migration. The inhibition of migration is greater in the 
UBE4B-depleted SK-N-AS cells than in parental cells or those transduced with a scrambled 
shRNA. A potential limitation of the cell migration assay was that measurements for migration 
were not blinded, which could have introduced bias. It would be ideal to re-score the saved 
DAPI-stained transwell membranes from the cell migration experiments using a blinded 
observer. This would provide additional validity to these results that suggest an anti-migratory 
effect of EGFR and STAT5 inhibition that is greater when UBE4B is depleted. Regardless, 
these data suggest that combined inhibition of EGFR and one of its downstream signaling 
partners, STAT5, may have a greater inhibitory effect on growth and cell migration in cells 
with low levels of UBE4B. 
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CHAPTER 7 – Discussion and Future Directions 
 
7.1 Overview  
 
High-risk neuroblastoma is associated with frequent relapses and tumors that are 
resistant to treatment (177) and children with refractory or recurrent neuroblastoma have very 
poor survival rates (4, 178, 179). We have previously observed that low UBE4B expression is 
associated with poor outcomes in patients with neuroblastoma (18). UBE4B is required for 
efficient degradation of the EGFR, and UBE4B protein levels are inversely related to EGFR 
protein levels (18), signaling (53), and cellular differentiation (19) in patient tumor samples. 
We screened a chemoresistant neuroblastoma cell line for intracellular proteins whose levels 
are altered when UBE4B is depleted. Interestingly, STAT5a was among the proteins whose 
levels were increased and it is also linked to EGFR-mediated proliferative signaling. We found 
that in contrast to inhibiting EGFR and STAT5 individually, targeting both EGFR and STAT5 
potentiated the inhibition of cell proliferation and migration, and promoted apoptosis in 
UBE4B-depleted SK-N-AS cells. These data suggest that multiplexed targeting of EGFR 
signaling may be an effective strategy for inhibition of growth when tumors have low levels 
of UBE4B. This may not be an effective approach, however, for patients with normal levels of 
UBE4B. Instead it should be viewed as a form of personalized cancer therapy for a particular 
patient subset: patients whose tumors express low amounts of UBE4B. 
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7.2 SK-N-AS as a Resistant Model Cell Line 
 
 The cell line SK-N-AS was determined to be more resistant to many of the conventional 
chemotherapy agents that we tested. SK-N-AS has been reported to be a resistant cell line (88) 
and it was originally cultured from a patient with metastasis to the bone (180). Like most of 
the cell lines that we tested (Table 2), it also has a deletion of the 1p chromosome site, which 
is the location of UBE4B (65). Low UBE4B protein levels correlate with poor prognosis (18, 
19), and this is consistent with the resistant behavior of that neuroblastoma cell line in our 
study.  
 The parental SK-N-AS line we used had detectable levels of UBE4B. Neuroblastoma 
is a very heterogeneous cancer (181) with variable expression of UBE4B throughout a single 
tumor (19). This heterogeneity is also another contributor to the variable chemotherapy 
response in neuroblastoma (181). After depletion of UBE4B, the doubling of EGFR protein 
levels seen here was consistent with earlier in vitro experiments in HeLa cervical 
adenocarcinoma cells using silencing RNA toward UBE4B (53). This supports the model 
suggesting that UBE4B ubiquitinates the EGFR at the endosomal membrane and promotes 
receptor degradation (53).  
 
7.3 Cetuximab Enhances the Growth Inhibition of Low Doses of Irinotecan In Vitro 
 
 We thought that a combination of irinotecan, a topoisomerase inhibitor, with the anti-
EGFR antibody Cetuximab might lower the IC50 necessary for irinotecan to inhibit SK-N-AS 
proliferation. SK-N-AS cells were more resistant to irinotecan than any other cell line we 
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examined, and upregulation of EGFR-mediated signaling has been shown to mediate 
irinotecan resistance (182). Additionally, in clinical literature, the combination of irinotecan 
and Cetuximab is specifically indicated for colorectal cancer that has become refractory to 
irinotecan (183). However, I observed that the IC50 achieved with irinotecan alone did not 
change significantly with the addition of Cetuximab. This lack of effect parallels a phase I 
clinical trial where irinotecan and Cetuximab were used in combination in pediatric solid 
tumors with no therapeutic benefit (76). This might be explained in part by the high cellular 
heterogeneity in neuroblastoma (181) leading to inconsistent response to treatments that are 
effective in other cancers. 
 One observation of note with the irinotecan and Cetuximab combination data, was that 
the anti-proliferative effect of the lowest doses of irinotecan did seem to be enhanced by the 
addition of Cetuximab. This may be because the inhibition of proliferative signaling pathways 
caused by EGFR binding by Cetuximab (66) is sufficient to amplify the effects of an agent like 
irinotecan which interferes with DNA replication. Clinically, this combination might be used 
to enhance the efficacy of smaller doses of irinotecan to limit the toxicities caused by this drug 
in children (184). 
 
7.4 UBE4B Depletion Increase Levels of Signaling Proteins (EGFR and STAT5a) 
 
Our study identified many proteins that are increased or decreased in amount following 
UBE4B depletion in neuroblastoma cells. Many of the upregulated proteins like SMAD4 (138) 
and PEA-15 (185), a tumor suppressor and a positive regulator of apoptosis respectively, are 
consistent with a cell inhibiting proliferation. However, other upregulated proteins like EGFR 
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and Signal Transducer and Activator of Transcription 5a  (STAT5) are consistent with a 
hyperproliferative state (186). A thorough review of the roles, pathways, and functions of 
proteins that increased or decreased in amount are provided in Table 3 and Table 4 in Chapter 
5. Of the proteins increased in amount that were identified for the model SK-N-AS cells 
depleted of UBE4B, there were several proteins associated with EGFR signal transduction 
pathways like MAP kinase/ERK, Akt/PI3K, and Jak/STAT (187).  We subsequently looked 
for ways to co-target EGFR and one of its downstream signaling pathways pharmacologically 
to test the hypothesis that a combination of agents that would inhibit multiple aspects of EGFR 
signaling might provide enhanced antiproliferative responses.  
EGFR and STAT5a both increased two-fold in UBE4B-depleted SK-N-AS cells. The 
regulation of EGFR trafficking by UBE4B has been described (53). The ubiquitination of 
STAT5a is a requisite step for its degradation, but the identity of that E3 ligase has not yet 
been established (188).  One possibility for the link between STAT5a and UBE4B is that 
UBE4B ubiquitinates STAT5a to promote its degradation.  Alternatively, UBE4B may lead to 
the ubiquitination and degradation of another protein which is a regulator of STAT5a. In either 
case, a decrease in UBE4B levels would lead to an increase in STAT5a levels. There was one 
other E3 ligase that was downregulated in our RPPA analysis, TRIM25, but we found no 
evidence of a demonstrated link between UBE4B and TRIM25, or between TRIM25 and 
STAT5a. Therefore, there is reason to believe that reduced ubiquitination of STAT5a might 
explain why it increased here, but the exact mechanism will require future investigation. 
 STAT5 is a member of the Jak/STAT signaling and it has been targeted with specific 
drugs as treatments for breast cancer (186), prostate cancer (173), and leukemia (189). STAT5 
levels are increased in proliferating tumors (190), and the Jak/STAT pathway is one of the 
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signaling cascades that may be activated by EGFR (171). Constitutive activation of STAT5 
can contribute to resistance to EGFR-targeted therapies (83).  There are also parallel examples 
of Jak/STAT inhibition combined with EGFR-targeted therapy in lung (85) and skin 
malignancies (174) to successfully inhibit cell growth. This led us to ask whether 
chemotherapeutic targeting of both EGFR and STAT5 could significantly decrease 
proliferation in model cells with a stable depletion of UBE4B. 
 There are seven proteins in the STAT family, including STAT1, STAT2, STAT3, 
STAT4, STAT5a, and STAT5b (171).  The proteins STAT3, STAT5a, and STAT5b are 
thought to have a role specifically in the development of cancer, while STAT1 has an opposite 
effect (190), and all transmit EGFR signals through the Jak/STAT pathway (191, 192). This 
signaling enhances proliferation, cell migration, and angiogenesis (193). STAT5a and STAT5b 
are highly similar isoforms of STAT5 that share 93% sequence homology (194, 195). Our 
RPPA data for the neuroblastoma SK-N-AS cell line depleted of UBE4B showed that there 
was a two-fold increase in STAT5 protein levels, and a 90% decrease in STAT3. In addition, 
phosphorylated STAT3 decreased by 56% when compared with parental and scrambled control 
lysates. STAT3 and STAT5 are good targets for inhibition to inhibit cancer’s growth (105), 
especially in hematologic malignancies (196). However, because of the large overlap between 
STAT3 and STAT5 in signal transmission, STAT5 inhibition may not be sufficient to decrease 
proliferation if STAT3 protein levels are high (171). In the case of our model SK-N-AS cell 
line, the lower levels of STAT3 and activated, phosphorylated STAT3 increase the opportunity 
for a STAT5 inhibitor to reduce neuroblastoma’s growth in vitro. 
 Our data suggest that inhibition of STAT5 by SH-4-54 is not highly effective by itself 
in inhibiting neuroblastoma cell proliferation in vitro regardless of whether UBE4B is depleted. 
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The dopamine antagonist pimozide, that also has STAT5 inhibitory activity, has been reported 
to have some anti-proliferative effect on SK-N-AS (169). In addition , STAT5 and STAT3 
have very similar roles in promoting signals for cancer proliferation (190), and there are several 
examples of STAT3 inhibitors used as a single agent (197) or in combination with a Jak 
inhibitor to successfully reduce neuroblastoma proliferation in vitro and tumor growth in vivo 
(198).  Even though STAT3 levels were lower in these model cells depleted of UBE4B, these 
examples provided an indication that STAT5 inhibition might be able to inhibit neuroblastoma 
cell growth. Doing so, however, might require a combination with another antiproliferative 
agent. 
 
7.5 UBE4B Depletion Enhances Sensitivity to Cetuximab, an anti-EGFR antibody 
 
 Our data demonstrate that the chemotherapy resistant neuroblastoma cell line SK-N-AS 
is more sensitive to Cetuximab-mediated EGFR inhibition than the tyrosine kinase inhibitor 
erlotinib. The growth inhibitory effect of Cetuximab suggests that at least some of the non-
degraded EGFR is located on the cell surface where it can be targeted by Cetuximab. 
Furthermore, the maximum Cetuximab dose used in a clinical trial with children having solid 
tumors was 250 mg/m2 (76), which equates to a serum concentration of less than 1 µM based 
on the average body mass and blood volume of an 18-month-old child (199). Thus, the 
Cetuximab concentrations used in this study may be in the therapeutic range for patients whose 
tumor cytology indicates low protein levels of UBE4B.   
 Erlotinib is a small molecule that binds to the intracellular tyrosine kinase domain of 
EGFR to prevent enzymatic function (200). It was used here as a control and an alternative 
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method of targeting EGFR. Our past cell growth assays with this drug agent have shown it to 
be ineffective slowing the growth of the neuroblastoma SK-N-AS line (data not shown). 
However, other studies have reported a 4 µM IC50 for erlotinib in wild type SK-N-AS 
neuroblastoma cells in vitro (91), and a phase I clinical trial with erlotinib has shown efficacy 
in patients (201). It is unclear why erlotinib was not effective at inhibiting growth in this study. 
Gefitinib, which also targets the tyrosine kinase activity of EGFR, is not effective at inhibiting 
neuroblastoma proliferation (202).  One explanation for the non-response to erlotinib may be 
that STAT5 activation specifically reduces sensitivity to erlotinib in other cancers (83). 
However, this still does not explain the similar behavior between wild type and UBE4B 
depleted cells since the non-depleted cells would be expected to have a growth inhibitory 
effect. It will be worth repeating this experiment with a new preparation of erlotinib and low 
passage SK-N-AS cells in the future to determine whether SK-N-AS is in fact non-responsive 
to erlotinib. Neuroblastoma is very heterogeneous, which affects the chemotherapy response 
(181), and long durations of cell passages in vitro could generate a cell population that is non-
responsive to erlotinib. 
 
7.6 Combination of STAT5 and EGFR Inhibition Reduces Neuroblastoma Growth, Promotes 
Apoptosis, and Reduces Migration In Vitro 
  
 Our data suggest that combined EGFR and STAT5 inhibition results in decreased 
neuroblastoma cell growth and increased apoptotic cell death. This finding parallels a study in 
chronic myelogenous leukemia (CML), that indicated high STAT5 levels mediated resistance 
to a small molecule tyrosine kinase inhibitors (189), and another study suggesting  that EGFR 
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blockade combined with Jak/STAT pathway inhibition was highly effective in epidermoid 
carcinoma (174). This combination therapy targets the EGFR to prevent ligand binding, reduce 
Jak/STAT signaling, and promote receptor degradation (Figure 17) (190). Cetuximab is 
unlikely to saturate all of the EGFR on a cell’s surface in vitro because of competitive 
inhibition with the ligand EGF (203), and small amounts of antibody actually reach tumors in 
vivo (204, 205). Therefore, dual inhibition of the receptor and one of its pathways may 
potentiate the effect of Cetuximab to achieve a more robust antiproliferative effect in vitro 
(Figure 15) (175). Cells expressing greater levels of EGFR, potentially on the cell surface, 
would have more targets for Cetuximab binding to promote cell death. Thus, this targets a pro-
proliferative phenotype of increased levels of EGFR to provide an additional treatment 
approach for neuroblastoma. 
 
66 
 
 
Figure 17. Combined EGFR and STAT5 blockade potentiates the effect of 
Cetuximab 
 
Cetuximab, an EGFR-specific antibody, binds to the EGFR on the surface of 
neuroblastoma to prevent ligand binding and induce receptor degradation. SH-4-54, 
a STAT5 inhibitor, blocks one of the pathways of EGFR proliferative signaling. The 
combined effect was observed to be greater than either agent alone. 
 
 
In addition to halting cell growth, there was evidence that the combination therapy also 
caused cell death. We observed decreased cell viability with the MTT assay at 72 hours when 
compared to the 24- and 48-hour time points, and microscopic examination suggested that cells 
were less adherent and dense at longer time points (data not shown). STAT5 normally activates 
anti-apoptotic pathways in cancer, and other studies have used a STAT5 null cell line to 
significantly enhance the apoptosis induction by a tyrosine kinase inhibitor (189). I found a 
significant increase in apoptosis when cells we treated with a combination of the STAT5 
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inhibitor SH-4-54 and the EGFR inhibitor Cetuximab, but there was no statistical difference 
between UBE4B depleted neuroblastoma cells and the control cells. EGFR inhibition with 
Cetuximab can cause cell death by autophagy in addition to apoptosis, especially when there 
are high levels of the autophagy-related gene (Atg) proteins (206). In the RPPA dataset, we 
saw a four-fold increase in Atg3 in SK-N-AS cells depleted of UBE4B (Figure 11). This may 
indicate that death in cells treated with Cetuximab and the STAT5 inhibitor SH-4-54 is 
occurring as a result of autophagy more so than apoptosis, especially in cells depleted of 
UBE4B.  
 Migratory behavior of tumor cells is one of the early signs of metastatic spread of cancer 
(170, 207), and metastasis to distant sites in the body is a hallmark of more advanced 
neuroblastoma disease (12). The epidermal growth factor receptor is also a key driver of wound 
healing on the skin, which is a migratory behavior of cells (208). We found that in UBE4B-
depleted neuroblastoma cells, treatment with EGFR and STAT5 inhibitors reduced transwell 
migration of the cancer cells in vitro. EGFR inhibition in glioma cells reduces migration in a 
similar manner (209). Given that about 70% of neuroblastoma patients have experienced 
metastatic disease at the time of initial diagnosis (7), this is an exciting finding requiring further 
examination. One pitfall to our present data is that it may not have appropriately taken into 
account cell death caused by the combination treatment. Pre-treated cells were counted with 
trypan blue, and the number of cells added to the transwell insert for migration experiments 
was based off of the number of live cells measured by that reagent. Trypan blue would not take 
into account the number of cells on the verge of death, however, so there may have been cells 
that failed to migrated because of death alone. An alternative method to both count the cells 
and assess viability before the migration assay would be to use flow cytometry with cell sorting 
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(FACS). In summary, these data indicate that in neuroblastoma cells expressing low amounts 
of UBE4B, a combination of a STAT5 inhibitor and Cetuximab can inhibit proliferation, 
induce cell death, and prevent cell migration that could lead to metastasis. 
 
 
7.7 Summary and Implications for Treatment 
 
We have observed that depletion of UBE4B can lead to increases in the levels of 
proteins involved in proliferation, including EGFR and STAT5a. EGFR inhibition using 
Cetuximab has growth inhibitory effects in UBE4B-depleted neuroblastoma cells at lower 
concentrations than has been seen previously in wild type cells (18). Finally, EGFR and 
STAT5 dual inhibition reduced proliferation, induced apoptosis, and slowed cell migration in 
UBE4B-depleted neuroblastoma cells more than either agent alone.  
Patients with refractory neuroblastomas often have fewer chemotherapeutic options. 
Their care team must rely on salvage chemotherapy, repeat autologous stem cell 
transplantation, radiotherapy, or immunotherapy to save the patient’s life (179, 210). The novel 
combination of EGFR and STAT5 inhibition described here may provide an additional option 
for refractory patients with a 1p36 deletion and lower levels of UBE4B. Given that surgical 
resection is the common first step for many neuroblastomas, it would be possible to measure 
UBE4B protein levels in patient tumors to determine whether they would be appropriate 
candidates.  
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7.8 Future Directions 
 
Orthotopic Animal Experiments 
One of the most critical areas for further exploration for this project will be to perform 
an in vivo experiment to test the antiproliferative effect of a combination of Cetuximab and the 
STAT5 inhibitor SH-4-54 in vivo.  An orthotopic xenograft model of neuroblastoma would be 
an appropriate model (211). Introduction of luciferase would enable tumor size tracking and 
modification of the UBE4B-depleted SK-N-AS cells to express luciferase would allow 
examination of tumor responses to EGFR and STAT5 treatments.  
Given the anti-proliferative, pro-apoptotic, and anti-migratory effect seen in the model 
neuroblastoma line in response to a combination treatment, we hypothesize that in vivo tumors 
grown from neuroblastoma cells with a depletion of UBE4B and then treated with this 
combination will have less tumor volume over a 5-week experiment, and they may also have 
lower incidence of metastasis. In this experiment we would monitor tumor volume with IVIS 
as well as body weight and survival time.  Following sacrifice we would weigh the excised 
tumors and perform immunoblotting for levels if UBE4B, EGFR, STAT5 as well as histologic 
analysis for CD31 to assess angiogenesis (212). 
 Neuroblastoma patients with a deletion at the 1p36 chromosomal location would 
potentially be responsive to EGFR and STAT5 inhibition as a form of treatment. About one-
third of neuroblastoma patients have this deletion in their cancer cells (14, 19). UBE4B levels 
could be tested in surgically resected tumors. Lower levels of UBE4B might indicate using this 
novel treatment approach, whereas it might be contraindicated in patients with tumors 
containing high levels of UBE4B. This kind of customized therapy for cancer patients is the 
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emerging wave of the future (213). Even though neuroblastoma is a relatively rare cancer and 
the number of patients treated in this manner would be potentially small, it could improve 
survival outcomes for certain high-risk patients. For those patients and their families, this could 
be incredibly important. 
 
 
Assessment of Additional EGFR and Signaling Pathway Combined Treatments 
 
 We focused on STAT inhibition here because of the elevated STAT5 and decreased 
STAT3 protein levels, which the literature indicated would make these model cells ideal for 
treatment with an EGFR and STAT inhibitor (171). Despite this, there are several examples 
in the literature where the AKT/PI3K pathway (214) or the MAPK/ERK (215) pathway have 
been targeted in neuroblastoma. Future studies could assess the growth inhibitory effects of 
those agents in these model cells when combined with Cetuximab. 
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